AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27214145 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled, nebulized AZD5423
Number of subjects: 0
Study 27214145 — intervention group
Group type: COMPARATOR
Intervention: Other biomarkers tested (osteocalcin, TRAP5b, DHEA-S, 4β-OH-cholesterol)
Number of subjects: 0
Study 24862742 — intervention group
Group type: COMPARATOR
Intervention: 40 mg of oral MPH
Number of subjects: 54
Study 23210418 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride test dentifrice
Number of subjects: 150
Study 23210418 — intervention group
Group type: COMPARATOR
Intervention: 0.30% triclosan/copolymer dentifrice
Number of subjects: 150
Study 20623459 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Interview of Personality Organization (STIPO) scales
Number of subjects: 104
Study 20623459 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical severity indicators (axis‐II comorbidity, suicide attempts, self‐destructive behaviour, service utilization)
Number of subjects: 104
Study 19002270 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 47
Study 19002270 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=24)
Number of subjects: 47
Study 15852173 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 56
Study 15852173 — intervention group
Group type: COMPARATOR
Intervention: CT-scan
Number of subjects: 56
Study 15852173 — intervention group
Group type: COMPARATOR
Intervention: b-mode and colour-duplex imaging
Number of subjects: 56
Study 15852173 — intervention group
Group type: EXPERIMENTAL
Intervention: CEUS
Number of subjects: 56
Study 12823852 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 49
Study 12823852 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 49
Study 11990437 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser in continuous mode with a focused beam of 0.8 mm (Group A)
Number of subjects: 30
Study 11990437 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser in pulsed mode with defocused beam of 4 mm (Group B)
Number of subjects: 30
Study 11990437 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls (Group C)
Number of subjects: 30
Study 10658377 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal protamine dose determined for residual heparin concentration (P group)
Number of subjects: 20
Study 10658377 — intervention group
Group type: COMPARATOR
Intervention: Initial fixed dose of protamine, 1.67 mg protamine per milligram total heparin (C group)
Number of subjects: 20
Study 8557059 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (20, 40, or 60 ng kg‐1 min‐1)
Number of subjects: 18
Study 8557059 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (40 ng kg‐1 min‐1)
Number of subjects: 18
Study 8557059 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (60 ng kg‐1 min‐1)
Number of subjects: 18
Study 8557059 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (40 or 60 ng kg‐1 min‐1)
Number of subjects: 18
Study 8557059 — intervention group
Group type: COMPARATOR
Intervention: 1.25 mg salbutamol
Number of subjects: 18
Study 2095163 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate
Number of subjects: 264
Study 2095163 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride
Number of subjects: 264
Study 2095163 — intervention group
Group type: COMPARATOR
Intervention: 10% glucose solution
Number of subjects: 264
Study 2095163 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 ml of 2% glucose solution)
Number of subjects: 264
Study 6985882 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day of UDCA
Number of subjects: 72
Study 6985882 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day of UDCA
Number of subjects: 72
Study 6985882 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 72
Study 31899739 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoblastic cell therapy
Number of subjects: 67
Study 31899739 — intervention group
Group type: COMPARATOR
Intervention: BMAC treatment
Number of subjects: 67
Study 31158840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl 20 mg
Number of subjects: 179
Study 31158840 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl 80 mg
Number of subjects: 179
Study 31158840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 31158840 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg
Number of subjects: 179
Study 28148682 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (25% of energy)
Number of subjects: 811
Study 28148682 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (15% of energy)
Number of subjects: 811
Study 25816354 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS without zinc, placebo tablet
Number of subjects: 2435
Study 25816354 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS containing 5mg zinc, placebo tablet
Number of subjects: 2435
Study 25816354 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS containing 10mg zinc, placebo tablet
Number of subjects: 2435
Study 25816354 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS without zinc and 5mg zinc tablet
Number of subjects: 2435
Study 25816354 — intervention group
Group type: COMPARATOR
Intervention: Control (NIC)
Number of subjects: 2435
Study 25816354 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS (IC)
Number of subjects: 2435
Study 23725208 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion recognition training
Number of subjects: 190
Study 23725208 — intervention group
Group type: COMPARATOR
Intervention: Control procedures
Number of subjects: 190
Study 21415814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring on two occasions, 7-15 days apart, on a stable antihypertensive regimen.
Number of subjects: 25
Study 19102810 — intervention group
Group type: EXPERIMENTAL
Intervention: FFQ for assessment of dietary EPA and DHA
Number of subjects: 65
Study 19102810 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish intake
Number of subjects: 65
Study 19102810 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fish intake
Number of subjects: 65
Study 19102810 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine food products intake
Number of subjects: 65
Study 17890725 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol flushing
Number of subjects: 158
Study 15351581 — intervention group
Group type: COMPARATOR
Intervention: HT soy grits
Number of subjects: 29
Study 11569761 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism regarding gains
Number of subjects: 0
Study 11569761 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism regarding losses
Number of subjects: 0
Study 11569761 — intervention group
Group type: EXPERIMENTAL
Intervention: Low optimism
Number of subjects: 0
Study 9149554 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 wrist flexion, 15 N resistance, 6 motions/min
Number of subjects: 7
Study 9149554 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 wrist flexion, 45 N resistance, 12 motions/min
Number of subjects: 7
Study 9149554 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 degrees wrist flexion, 45 N resistance, 15 motions/min
Number of subjects: 7
Study 9149554 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 7
Study 8182996 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis with antacids and H2 blockers (AA+H2)
Number of subjects: 51
Study 8182996 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis with sucralfate
Number of subjects: 51
Study 8182996 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study 3241118 — intervention group
Group type: EXPERIMENTAL
Intervention: Keyboard
Number of subjects: 20
Study 3241118 — intervention group
Group type: EXPERIMENTAL
Intervention: Light Pen
Number of subjects: 20
Study 3241118 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Recognition
Number of subjects: 20
Study 30148388 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing on honesty in communication for 3 days
Number of subjects: 0
Study 30148388 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in specific honest conversations (disclosing personal information)
Number of subjects: 0
Study 30148388 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging in specific honest conversations (sharing negative feedback)
Number of subjects: 0
Study 30148388 — intervention group
Group type: COMPARATOR
Intervention: Being kind in communication for 3 days
Number of subjects: 0
Study 30148388 — intervention group
Group type: COMPARATOR
Intervention: Being conscious of communication for 3 days
Number of subjects: 0
Study 26060092 — intervention group
Group type: COMPARATOR
Intervention: Rowing (ROW)
Number of subjects: 13
Study 26060092 — intervention group
Group type: COMPARATOR
Intervention: Cycling (CYC)
Number of subjects: 13
Study 23887932 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated grief group therapy (CGGT)
Number of subjects: 100
Study 23887932 — intervention group
Group type: COMPARATOR
Intervention: Standard group therapy (treatment as usual [TAU])
Number of subjects: 100
Study 22106987 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalization (mentioning recipient's first name three times in the text) with strong arguments
Number of subjects: 120
Study 22106987 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalization (mentioning recipient's first name three times in the text) with weak arguments
Number of subjects: 120
Study 22106987 — intervention group
Group type: COMPARATOR
Intervention: Standard (no personalization) with strong arguments
Number of subjects: 120
Study 22106987 — intervention group
Group type: COMPARATOR
Intervention: Standard (no personalization) with weak arguments
Number of subjects: 120
Study 20357174 — intervention group
Group type: EXPERIMENTAL
Intervention: 54 mg of genistein aglycone daily (n = 71)
Number of subjects: 389
Study 20357174 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 67)
Number of subjects: 389
Study 19337553 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 504
Study 19337553 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 20 mg
Number of subjects: 504
Study 15703931 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET in hyperglycaemic DM
Number of subjects: 219
Study 15703931 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET in euglycaemic DM
Number of subjects: 219
Study 15703931 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET in non-DM
Number of subjects: 219
Study 15703931 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET (all DM patients)
Number of subjects: 219
Study 15317925 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous fracture
Number of subjects: 4292
Study 15317925 — intervention group
Group type: EXPERIMENTAL
Intervention: A fall in the last 12 months
Number of subjects: 4292
Study 15317925 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (per year increase)
Number of subjects: 4292
Study 15317925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low body weight (<58 kg)
Number of subjects: 4292
Study 15317925 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal history of hip fracture
Number of subjects: 4292
Study 11029334 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microgram orally inhaled budesonide plus 200 microgram intranasal budesonide (BUD)
Number of subjects: 14
Study 11029334 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ)
Number of subjects: 14
Study 8610727 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration (usual dose)
Number of subjects: 8
Study 8610727 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous administration (1.75-fold dose)
Number of subjects: 8
Study 8610727 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable pump therapy (1.75-fold dose)
Number of subjects: 8
Study 8610727 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable pump therapy (usual dose)
Number of subjects: 8
Study 1426394 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 246
Study 1426394 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 246
Study 3914839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 43
Study 3914839 — intervention group
Group type: COMPARATOR
Intervention: Estrogen
Number of subjects: 43
Study 3914839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (secondary therapy)
Number of subjects: 43
Study 3914839 — intervention group
Group type: COMPARATOR
Intervention: Estrogen (secondary therapy)
Number of subjects: 43
Study 3695527 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with Dacarbazine (DTIC) 200 mg/M2 I.V. daily X 5 every 4 weeks and Estracyt 15 mg/kg orally daily for 1 year
Number of subjects: 82
Study 3695527 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with TICE BCG 1 ml to an area of scarification near the primary site, every 4 weeks for 1 year
Number of subjects: 82
Study 3695527 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 82
Study 3695527 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic status of the regional nodes
Number of subjects: 82
Study 31119438 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq™
Number of subjects: 26
Study 31119438 — intervention group
Group type: COMPARATOR
Intervention: GlideScope®
Number of subjects: 26
Study 29135993 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovator tacrolimus
Number of subjects: 71
Study 29135993 — intervention group
Group type: COMPARATOR
Intervention: Generic Hi
Number of subjects: 71
Study 29135993 — intervention group
Group type: COMPARATOR
Intervention: Generic Lo
Number of subjects: 71
Study 29135993 — intervention group
Group type: EXPERIMENTAL
Intervention: All products
Number of subjects: 71
Study 26391858 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MR diagnostic work-up (standard preoperative diagnostic work-up + MRC)
Number of subjects: 56
Study 26391858 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative diagnostic work-up
Number of subjects: 56
Study 23183390 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise (HI‐IE)
Number of subjects: 15
Study 23183390 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Exercise (MI‐CE)
Number of subjects: 15
Study 21518170 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy
Number of subjects: 39
Study 21518170 — intervention group
Group type: COMPARATOR
Intervention: Calculation training (Control)
Number of subjects: 39
Study 17933005 — intervention group
Group type: EXPERIMENTAL
Intervention: Beger procedure
Number of subjects: 40
Study 17933005 — intervention group
Group type: COMPARATOR
Intervention: pylorus-preserving Whipple procedure
Number of subjects: 40
Study 17024871 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 17024871 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 0
Study 17024871 — intervention group
Group type: COMPARATOR
Intervention: Postoperative radiation therapy (PORT)
Number of subjects: 0
Study 17024871 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 0
Study 12137243 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation challenge with (1‐‐>3)‐beta‐D‐glucan
Number of subjects: 35
Study 12137243 — intervention group
Group type: COMPARATOR
Intervention: Saline inhalation challenge
Number of subjects: 35
Study 9740934 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical infraclavicular block (VIP1)
Number of subjects: 0
Study 9740934 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical infraclavicular block (VIP2)
Number of subjects: 0
Study 9740934 — intervention group
Group type: COMPARATOR
Intervention: Axillary block (AX)
Number of subjects: 0
Study 8543745 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low allergen diet (milk-, egg-, wheat-, nut-free)
Number of subjects: 115
Study 8543745 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 115
Study 2220622 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 20
Study 2220622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 353387 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram implantation
Number of subjects: 20
Study 353387 — intervention group
Group type: COMPARATOR
Intervention: Placebo implantation
Number of subjects: 20
Study 29119296 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection (1 ml of Depo-Medrol, 40 mg)
Number of subjects: 66
Study 29119296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 66
Study 27491847 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL)
Number of subjects: 60
Study 27491847 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation exercises (SE)
Number of subjects: 60
Study 27491847 — intervention group
Group type: COMPARATOR
Intervention: Control group (didactic teaching only)
Number of subjects: 60
Study 23331760 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective sun protection messages
Number of subjects: 0
Study 23331760 — intervention group
Group type: EXPERIMENTAL
Intervention: Ineffective sun protection messages
Number of subjects: 0
Study 23331760 — intervention group
Group type: COMPARATOR
Intervention: Fear appeal (cancer vs. appearance)
Number of subjects: 0
Study 23331760 — intervention group
Group type: COMPARATOR
Intervention: Neutral fear appeal
Number of subjects: 0
Study 22239915 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral constant-current deep brain stimulation (DBS) of the subthalamic nucleus
Number of subjects: 136
Study 22239915 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed stimulation)
Number of subjects: 136
Study 22239915 — intervention group
Group type: COMPARATOR
Intervention: Both groups (stimulation and control)
Number of subjects: 136
Study 19955397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional advice from a brochure
Number of subjects: 195
Study 19955397 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure and lifestyle education by a nutritionist
Number of subjects: 195
Study 19955397 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study 18672763 — intervention group
Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin Pill (SBP) 2 pills, taken orally three times per day for 6 months
Number of subjects: 200
Study 18672763 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy for CHD (anti-platelet, lipid regulating, anti-ischemia)
Number of subjects: 200
Study 16898535 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment (60 mg/m2/48h) in children in relapse (Group A, n=24)
Number of subjects: 66
Study 16898535 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid treatment (30 mg/m2/48h) in children in remission (Group B, n=20)
Number of subjects: 66
Study 16898535 — intervention group
Group type: COMPARATOR
Intervention: No steroid treatment in children in remission (Group C, n=22)
Number of subjects: 66
Study 16898535 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=20)
Number of subjects: 66
Study 12803733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 0
Study 12803733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 0
Study 12803733 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 0
Study 12803733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10583422 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II i.v. for 6 h (1-3 microgram min-1)
Number of subjects: 72
Study 10583422 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II + captopril
Number of subjects: 72
Study 10583422 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 72
Study 10583422 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 72
Study 10583422 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II + losartan
Number of subjects: 72
Study 8934009 — intervention group
Group type: EXPERIMENTAL
Intervention: Resecting scar tissues, molding the closed glottis, and stenting a patent laryngeal lumen until consolidation
Number of subjects: 0
Study 2011407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg b.i.d.)
Number of subjects: 142
Study 2011407 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin + clavulanic acid or erythromycin
Number of subjects: 142
Study 7336474 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 0
Study 7336474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29671172 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain wheat bread (WW diet)
Number of subjects: 50
Study 29671172 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat bread (RW diet)
Number of subjects: 50
Study 24249544 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose trivalent inactivated influenza vaccine (60 µg)
Number of subjects: 50
Study 24249544 — intervention group
Group type: COMPARATOR
Intervention: Standard dose trivalent inactivated influenza vaccine (15 µg)
Number of subjects: 50
Study 22017808 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy plus treatment as usual (MBCT+TAU)
Number of subjects: 205
Study 22017808 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 205
Study 20308699 — intervention group
Group type: EXPERIMENTAL
Intervention: 90‐min daytime nap at 11:30
Number of subjects: 6
Study 20308699 — intervention group
Group type: COMPARATOR
Intervention: 90‐min daytime nap at 10:30
Number of subjects: 6
Study 20308699 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐h time interval between training and nap
Number of subjects: 6
Study 20308699 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐h time interval between training and nap
Number of subjects: 6
Study 18602634 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate removal of urethral catheter
Number of subjects: 200